quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable

View original at finance.yahoo.com
JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The average Return on Equity used in the Excess Returns model is 16.96%, with a cost of equity of US$11.65 per share and an excess return of US$13.00 per share

    60% confidence

  • Analysts estimate a stable earnings figure of US$24.65 per share and a stable book value of US$145.37 per share for JPMorgan Chase, based on forward-looking ROE inputs from 12 analysts

    60% confidence

  • Over 7 million investors trust Simply Wall St for stock portfolio updates

    60% confidence

  • JPMorgan Chase stock is approximately 24.0% undervalued based on the Excess Returns valuation model, with an intrinsic value estimate of US$435.81 per share versus a market price of US$331.14

    60% confidence

  • JPMorgan Chase scores just 2 out of 6 on Simply Wall St's valuation checks, with multiple red flags identified

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
JPMorgan Chase (JPM) Stock After 25% Yearly Gain Is The Price Still Reasonable — Source | Via News | pt.VIA.NEWS